ClinicalTrials.gg
RecruitingNCT06760039Updated Apr 3, 2025

Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL

A Phase 1/2 interventional study of R-CMOP Regimen and R-CHOP Regimen in Diffuse Large B-Cell Lymphoma, sponsored by Sun Yat-sen University. Recruiting at 10 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by Sun Yat-sen University · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Lymphoma, Large B-Cell, Diffuse by Sun Yat-sen University — 10 open to participants now, 10 under way, 1 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Sun Yat-sen University.

Planned enrollment
2nd of 13
112 · median 48
Started
2025
with 2 others
Phase 1/2
3 of 17
3 open now
Registered
11th of 17
by date

Among the 17 studies in Lymphoma, Large B-Cell, Diffuse by Sun Yat-sen University, this one is the 2nd largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2025, is one of 3 in phase 1/2, and was the 11th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

10 of the 17 studies in Lymphoma, Large B-Cell, Diffuse by Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Lymphoma, Large B-Cell, Diffuse by Sun Yat-sen University, or all of them as a file.
02

Study summary

This is a prospective, randomized, controlled, multicenter, phase II clinical trial to evaluate the efficacy and safety of R-CMOP versus R-CHOP in the initial treatment of low-risk and medium-risk diffuse large B-cell lymphoma (DLBCL).

03

Conditions studied

  • Diffuse Large B-Cell Lymphoma

Keywords

  • DLBCL
  • R-CHOP
  • Liposomal Mitoxantrone
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Aged ≥18,≤80 years, both male and female.
  2. confirmed DLBCL
  3. No prior treatment for DLBCL.
  4. There must be at least one measurable or evaluable lesion that meets the evaluation criteria for Lugano 2014 lymphoma.
  5. (ECOG) performance status score of 0-
  6. Expected survival ≥3 months.
  7. International Prognostic Index (IPI) ≤ 2
  8. Sufficient bone marrow, liver, and kidney function.

Key Exclusion Criteria:

  1. Other types of LBCL:Primary Cutaneous Diffuse Large B-cell Lymphoma (Leg Type), Primary Mediastinal (Thymic) Large B-cell Lymphoma, Lymphomatoid Granulomatosis, ALK-positive Diffuse Large B-cell Lymphoma, Plasmablastic Lymphoma, Intravascular Large B-cell Lymphoma, T-cell/Histiocyte-rich Large B-cell Lymphoma, and others.
  2. Transformed DLBCL.
  3. Patients with central nervous system involvement, or those who require high-dose methotrexate for prevention.
  4. The patients had previously received antitumor therapy.
  5. Patients with the infection of (HIV) and/or acquired immunodeficiency syndrome.
  6. Pregnant and lactating women and subjects of childbearing age who do not want to use .
  7. Mentally ill persons or persons unable to obtain .
  8. The investigators think that the patient is not suitable for the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    Experimental group

    R-CMOP group

    Drug: R-CMOP Regimen

  • Active comparator
    Control group

    R-CHOP group

    Drug: R-CHOP Regimen

Interventions

  • DrugR-CMOP Regimen

    Rituximab intravenous drip, Cyclophosphamide intravenous drip, Liposomal Mitoxantrone intravenous drip, Vincristine intravenous drip, Prednisone orally

  • DrugR-CHOP Regimen

    Rituximab intravenous drip, Cyclophosphamide intravenous drip, Doxorubicinin intravenous drip, Vincristine intravenous drip, Prednisone orally

06

What researchers measure

Primary outcomes

  1. 2-year event-free survival (EFS) rate assessed by the independent review committee

    To investigate the antitumor efficacy

    Time frame: Defined as the proportion of patients without disease progresion, treatment discontinuation, or death for any reason within 24 months of enrollment, based on the independent review committee's assessment.

  2. RP2D(Phase Ib)

    Phase II Recommended Dose

    Time frame: Cycle 1 in R-CMOP group (28 days)

  3. DLT(Phase Ib)

    Dose-limiting toxicity

    Time frame: Cycle 1 in R-CMOP group (28 days)

Secondary outcomes

  1. 2-year event-free survival (EFS) rate assessed by the investigators

    To investigate the anti-tumor efficacy

    Time frame: Defined as the proportion of patients without disease progresion, treatment discontinuation, or death for any reason within 24 months of enrollment, based on the investigators' assessment.

  2. AE and SAE (Phase Ib)

    Number of participants with adverse events (AE) and severe adverse events (SAE) in phase Ib

    Time frame: Up to 24 weeks

  3. 2-year Progression-free survival(PFS)

    To investigate the antitumor efficacy

    Time frame: Defined as the proportion of patients without disease progresion, treatment discontinuation, or death for any reason within 24 months of enrollment

  4. 2-year Overall survival(OS)

    To investigate the antitumor efficacy

    Time frame: Defined as the proportion of patients without disease progresion, treatment discontinuation, or death for any reason within 24 months of enrollment

  5. Objective response rate (ORR)

    To investigate the antitumor efficacy

    Time frame: Up to 24 weeks

  6. Complete response rate (CRR)

    To investigate the antitumor efficacy

    Time frame: Up to 24 weeks

07

Study locations

2 of 10 sites recruiting
  • Fujian Provincial Cancer Hospital
    Fuzhou, Fujian, China
    Not yet recruiting
    • Hongming He · Contact13799361913
  • Gansu Provincial Cancer Hospital
    Lanzhou, Gansu, China
    Not yet recruiting
    • Junfeng Jiang · Contact13893332604
  • The Fifth Affiliated Hospital of Guangzhou Medical University.
    Guangzhou, Guangdong 510060, China
    Recruiting
    • Runhui Zheng · Contact13560225061
  • The Affiliated Hospital of Guangdong Medical University
    Guangzhou, Guangdong, China
    Not yet recruiting
  • Shenzhen People's Hospital
    Shenzhen, Guangdong, China
    Not yet recruiting
    • Jihao Zhou · Contact18718678693
  • The Fifth Affiliated Hospital of Sun Yat-sen University
    Zhuhai, Guangdong, China
    Recruiting
    • Nan Chen · Contact13631270598
  • Guangxi Zhuang Autonomous Region Cancer Hospital
    Guilin, Guangxi, China
    Not yet recruiting
    • Hong Cen · Contact13507711671
  • Ganzhou Cancer Hospital
    Ganzhou, Jiangxi, China
    Not yet recruiting
    • Qingfang Zeng · Contact13870711700
  • Jiangxi Provincial Cancer Hospital
    Nanchang, Jiangxi, China
    Not yet recruiting
    • Wuping Li · Contact13870659916
  • Beijing Tongren Hospital
    Beijing, China
    Not yet recruiting
    • Liang Wang · Contact15001108693
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Aug 2028, 43 months after the start.

Of 57 non-industry phase 1/2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 94. This study's planned 43 months is below that.

Counting every sponsor, half of 108 studies reached it within 70 months; a quarter within 50 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2024
First posted
Jan 6, 2025
StartActual
Jan 10, 2025
Primary completionEst.
Aug 31, 2028
CompletionEst.
Nov 30, 2028
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06760039
Responsible party
Qingqing Cai (Professor, Sun Yat-sen University) — Principal investigator
First posted
Jan 6, 2025
Start date
Jan 10, 2025
Primary completion
Aug 31, 2028 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
Apr 3, 2025

Study contacts

Qingqing Cai, MD. PhD.
Contact
caiqq@sysucc.org.cn
0086-20-87342823

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion